San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Revelation Biosciences is raising $5,144,458.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Chester Zygmont played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Revelation Biosciences

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of innate immune system therapeutics and diagnostics for the prevention and treatment of disease. The Company has several product candidates in development. REVTx99, the lead therapeutic candidate, a broad anti-viral nasal drop solution that can be used to prevent or treat respiratory viral infections, including Influenza A, Influenza B, parainfluenza, rhinovirus, respiratory syncytial virus and SARS-CoV-2 including its variants. REVTx-99 works by boosting the body’s innate immune system, preventing the user from becoming infected or activating the innate immune to combat early infections. REVTx200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx501, a rapid point of care diagnostic that can be used to detect various respiratory viral infections regardless of virus type without the need for specialized instrumentation.

To learn more about Revelation Biosciences, visit http://www.revbiosciences.com/

Contact:
Chester Zygmont, Chief Financial Officer
650-800-3717
czygmont@revbiosciences.com
https://www.linkedin.com/in/chetszygmont/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved